REGENXBIO to Participate in Upcoming Investor Conferences
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming virtual investor conferences in June 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in two upcoming virtual investor conferences in June 2021. The Bank of America 2021 Napa Biopharma Virtual Conference will feature a fireside chat on June 16, 2021, at 12:30 p.m. E.T. Additionally, the Raymond James Human Health Innovation Conference is scheduled for June 21, 2021. Investors can access the live webcast of the Bank of America event on REGENXBIO's website, with an archived replay available for 30 days thereafter. REGENXBIO focuses on gene therapy through its proprietary NAV Technology Platform.
Details
News Market Reaction – RGNX
The recorded move for RGNX in the trading session of this news was -0.40%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ROCKVILLE, Md., June 9, 2021 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following June investor conferences, which will each be held in a virtual meeting format:
Bank of America 2021 Napa Biopharma Virtual Conference
Fireside Chat: Wednesday, June 16, 2021 at 12:30 p.m. E.T.
Raymond James Human Health Innovation Conference
Date: Monday, June 21, 2021
A live webcast of the Bank of America fireside chat can be accessed in the 'Investors' section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available on the same website for approximately 30 days following the fireside chat.
About REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of candidates in multiple therapeutic areas.
Contacts:
Tricia Truehart
Investor Relations and Corporate Communications
347-926-7709
ttruehart@regenxbio.com
Investors:
Brendan Burns, 212-600-1902
brendan@argotpartners.com
Media:
David Rosen, 212-600-1902
david.rosen@argotpartners.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/regenxbio-to-participate-in-upcoming-investor-conferences-301308489.html
SOURCE REGENXBIO Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.